These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 12077088

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
    Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, Tami J, Dorr FA, Sewell KL.
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
    [Abstract] [Full Text] [Related]

  • 3. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease.
    Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, Hahn EG, Krummenerl T, Steinmann G, German ICAM-1 Study Group.
    Gastroenterology; 2001 May; 120(6):1339-46. PubMed ID: 11313303
    [Abstract] [Full Text] [Related]

  • 4. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
    Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR.
    Gastroenterology; 1998 Jun; 114(6):1133-42. PubMed ID: 9609749
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
    Yacyshyn BR, Schievella A, Sewell KL, Tami JA.
    Clin Exp Immunol; 2005 Jul; 141(1):141-7. PubMed ID: 15958080
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Alicaforsen. Isis Pharmaceuticals.
    Gewirtz AT, Sitaraman S.
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
    Yacyshyn B, Bowen-Yacyshyn MB, Shanahan W.
    Curr Opin Mol Ther; 1999 Jun; 1(3):332-5. PubMed ID: 11713798
    [Abstract] [Full Text] [Related]

  • 13. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.
    Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F.
    N Engl J Med; 2015 Mar 19; 372(12):1104-13. PubMed ID: 25785968
    [Abstract] [Full Text] [Related]

  • 14. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.
    Miner P, Wedel M, Bane B, Bradley J.
    Aliment Pharmacol Ther; 2004 Feb 01; 19(3):281-6. PubMed ID: 14984374
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Vedolizumab as induction and maintenance therapy for Crohn's disease.
    Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A, GEMINI 2 Study Group.
    N Engl J Med; 2013 Aug 22; 369(8):711-21. PubMed ID: 23964933
    [Abstract] [Full Text] [Related]

  • 17. Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial.
    Reinisch W, Knobler R, Rutgeerts PJ, Ochsenkühn T, Anderson F, von Tirpitz C, Kaatz M, Janneke van der Woude C, Parenti D, Mannon PJ.
    Inflamm Bowel Dis; 2013 Feb 22; 19(2):293-300. PubMed ID: 22573600
    [Abstract] [Full Text] [Related]

  • 18. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D, Macdonald JK, Chande N.
    Cochrane Database Syst Rev; 2014 Feb 21; (2):CD010410. PubMed ID: 24558033
    [Abstract] [Full Text] [Related]

  • 19. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
    Miner PB, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK.
    Aliment Pharmacol Ther; 2006 May 15; 23(10):1427-34. PubMed ID: 16669957
    [Abstract] [Full Text] [Related]

  • 20. ISIS 2302. Oligo-TCS.
    Drugs R D; 1999 Mar 15; 1(3):265-7. PubMed ID: 10566042
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.